Discovery of Novel 5-Cyano-3-phenylindole-Based LSD1/HDAC Dual Inhibitors for Colorectal Cancer Treatment
Journal of Medicinal Chemistry · 28.11.2024 · 67 (22) · 20172-20202
DOI: 10.1021/acs.jmedchem.4c01524 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 14.11.2024. Verfasst von Hui-Juan Zhu und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Xinxiang Medical University, Xinxiang, Henan 453003, PR China. Hauptthemen laut MEDLINE: Histone Demethylases, Colorectal Neoplasms, Histone Deacetylase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: Natural Science Foundation of Henan Province, Science and Technology Innovation Talents in Universities of Henan Province, Henan Province Foundation for University Key Teacher.
Abstract (Originalsprache)
The dual inhibition of histone lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) has emerged as a promising strategy for cancer therapy. In this study, we report the discovery of novel 5-cyano-3-phenylindole-based LSD1/HDAC dual inhibitors, evaluated through both in vitro and in vivo assays. Among these inhibitors, compound 20c was identified as particularly potent, exhibiting high inhibitory activity against LSD1 (IC50 = 39.0 nM) and HDAC1/2/3/6/8 (IC50 = 1.4, 1.0, 1.3, 2.9, and 16.0 nM, respectively). Compound 20c effectively modulated the expression of biomarkers associated with LSD1 and HDAC inhibition and demonstrated superior antiproliferative activity compared to SAHA and 4SC-202 across multiple colorectal cancer cell lines. Following pharmacokinetic studies, 20c was further assessed in HCT-116 and HT-29 xenograft mouse models. It demonstrated significantly enhanced antitumor efficacy compared to SAHA, without causing observable toxicity. These findings highlight the potential of LSD1/HDAC dual inhibitors for the treatment of malignant cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Xinxiang Medical University, Xinxiang, Henan 453003, PR China.
- School of Medical Engineering, Xinxiang Medical University, Xinxiang, Henan 453003, PR China.
- Department of Oncology, Henan Province Engineering Research Center for of Intractable Digestive Tract Tumor Precision Therapy & Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer, The Affiliated C…
- Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Laboratory Animal Center, State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, Henan Provin…
ORCID-Profile: Xiao-Jing Shi, Ying-Chao Duan
Förderung
- Natural Science Foundation of Henan Province
- Science and Technology Innovation Talents in Universities of Henan Province
- Henan Province Foundation for University Key Teacher
- National Natural Science Foundation of China
Zitieren
APA
Zhu, H. J., Zhou, H. M., Zhou, X. X., Li, S. J., Zheng, M. J., Xu, Z., Dai, W. J., Ban, Y. B., Zhang, M. Y., Zhang, Y. Z., Lu, J. R., Xu, Y. T., Wang, S. Q., Shi, X. J., & Duan, Y. C. (2024). Discovery of Novel 5-Cyano-3-phenylindole-Based LSD1/HDAC Dual Inhibitors for Colorectal Cancer Treatment. Journal of Medicinal Chemistry, 67(22), 20172-20202. https://doi.org/10.1021/acs.jmedchem.4c01524
Vancouver
Zhu HJ, Zhou HM, Zhou XX, Li SJ, Zheng MJ, Xu Z, et al. Discovery of Novel 5-Cyano-3-phenylindole-Based LSD1/HDAC Dual Inhibitors for Colorectal Cancer Treatment. Journal of Medicinal Chemistry. 2024;67(22):20172-20202. doi:10.1021/acs.jmedchem.4c01524
BibTeX
@article{Zhu2024,
author = {Zhu, Hui-Juan and Zhou, Hui-Min and Zhou, Xiao-Xiao and Li, Shi-Jie and Zheng, Meng-Jie and Xu, Zhen and Dai, Wen-Jing and Ban, Yi-Bo and Zhang, Meng-Yao and Zhang, Yi-Zhe and Lu, Jia-Rui and Xu, Yong-Tao and Wang, Sai-Qi and Shi, Xiao-Jing and Duan, Ying-Chao},
title = {Discovery of Novel 5-Cyano-3-phenylindole-Based LSD1/HDAC Dual Inhibitors for Colorectal Cancer Treatment},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {22},
pages = {20172--20202},
doi = {10.1021/acs.jmedchem.4c01524}
}
EUVIMED